The Egyptian Drug Authority (EDA) announced, on Saturday, the launch of the programme to certify the results issued by quality control laboratories at Egypt’s pharmaceutical companies.
The move comes as part of efforts to support pharmaceutical investment in Egypt.
EDA spokesperson Mahmoud Yassin said the programme aims to improve the level of the country’s drug industry and the supervisory performance of the quality control laboratories at pharmaceutical companies.
He noted that the authority will grant a certificate approving the results of analyses conducted by quality control laboratories at pharmaceutical companies, according to standards set by the authority.
Medhat El-Ghobashy, Head of the Central Department of Drug Control at the EDA, said that the accreditation programme will reduce the time required to examine pharmaceutical preparations and to issue analysis. This will in turn help to provide quality and safe medicine for citizens.
He said that strengthening the quality control model through accreditation programmes has become one of the most important priorities that contribute to develop the drug industry.
El-Ghobashy asserted that the EDA had established the programme in line with the ISO 17025 certificate’s specifications, related to the general requirements for the competence of analysis laboratories.
The authority launched the programme in cooperation with industry partners, to ensure the availability of safe and effective treatments with the highest quality standards. It aims to encourage investment in the pharmaceutical sector in Egypt, and to enhance the export capacity of the pharmaceutical industries.
The programme launched by the authority represents a leap in the pharmaceutical industry in Egypt, in line with the latest regulations applied globally. It will in turn contribute to the application of the highest quality standards in drug manufacturing.
